Abstract
Background:
Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC). This study, part of the ENTHUSE (EndoTHelin A USE) phase III programme, evaluated the efficacy and safety of the oral specific endothelin (ET)A receptor antagonist zibotentan vs placebo in patients with non-metastatic CRPC (non-mCRPC).
Methods:
This was a multicentre, randomized, double-blind, phase III study. Patients (n=1421) with non-mCRPC and biochemical progression (determined by rising serum PSA levels) were randomized to receive zibotentan 10 mg or placebo once daily. Based on the lack of efficacy signal in another ENTHUSE phase III study, an interim analysis was performed to determine whether the study was likely to achieve the co-primary objectives of improved overall survival (OS) and progression-free survival (PFS).
Results:
Criteria for continuation of this study were not met. A total of 79 deaths and 293 progression events were recorded at final data cutoff. Zibotentan-treated patients did not significantly differ from placebo-treated patients for OS (hazard ratio (HR): 1.13; 95% confidence interval (CI): 0.73–1.76, P=0.589) or PFS (HR: 0.89; 95% CI: 0.71–1.12, P=0.330). The most commonly reported adverse events in zibotentan-treated patients were peripheral oedema (37.7%), headache (26.2%) and nasal congestion (24.9%); each occurred with >15% higher incidence than in the placebo group.
Conclusions:
This trial was terminated early because of failure at interim analysis of the efficacy data to meet the defined criteria for continuation. Owing to the absence of demonstrable survival benefits in the ENTHUSE clinical studies, zibotentan is no longer under investigation as a potential treatment for prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
Mostaghel EA, Nelson PS . Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 243–258.
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918–2925.
Smith MR, Cook R, Lee KA, Nelson JB . Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011; 117: 2077–2085.
Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J . Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011; 163: 220–233.
Nelson JB . Endothelin inhibition: novel therapy for prostate cancer. J Urol 2003; 170: S65–S68.
James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase II trial. Eur Urol 2009; 55: 1112–1123.
James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int 2010; 106: 966–973.
Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW et al. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J Urol 2012; 188: 103–109.
Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H et al. Phase III, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012; 118: 5709–5718.
Armstrong AJ, Creel P, Turnbull J, Moore C, Jaffe TA, Haley S et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14: 6270–6276.
Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67: 3818–3826.
Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A . ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007; 6: 2003–2011.
Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, Burris HA et al. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate 2011; 71: 1264–1275.
Fizazi K, Higano C, Nelson J, Gleave M, Miller K, Morris T et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer. Submitted to J Clin Oncol 2012.
Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679–689.
Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003; 169: 1143–1149.
Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959–1966.
Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113: 2478–2487.
SWOG Press Release. Addition of atrasentan to standard chemotherapy for advanced prostate cancer shows no benefit in phase III clinical trial. SWOG 2012; Internet Communication.
Warren R, Liu G . ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 2008; 17: 1237–1245.
Liu G, Dreicer R, Hou J, Chen Y, Wilding G . Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptor-specific antagonism. J Clin Oncol 2005; 23, abst 4628.
Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D . A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007; 17: 584–590.
Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K . What do prostate cancer patients die of? Oncologist 2011; 16: 175–181.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39–46.
FDA. ODAC Briefing Document BLA 125320/28 Denosumab (Xgeva). Amgen 8 February. 2012. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290400.pdf.
Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G et al. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012; 3: 73.
Acknowledgements
We thank Zoë van Helmond, PhD from Mudskipper Bioscience who provided writing assistance funded by AstraZeneca.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
KM is a consultant to AstraZeneca (AZ), Astellas and Janssen–Cilag; JWM is a paid consultant of AZ; MG, KF and CSH participated in an AZ advisory board; JBN is a paid consultant of AZ; TM, FEN, SM and KP are all employees of AZ and have stock ownership.
Rights and permissions
About this article
Cite this article
Miller, K., Moul, J., Gleave, M. et al. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 16, 187–192 (2013). https://doi.org/10.1038/pcan.2013.2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2013.2
Keywords
This article is cited by
-
Treatment and trials in non-metastatic castration-resistant prostate cancer
Nature Reviews Urology (2021)
-
Ultrasound-assisted, low-solvent and acid/base-free synthesis of 5-substituted 1,3,4-oxadiazole-2-thiols as potent antimicrobial and antioxidant agents
Molecular Diversity (2021)
-
Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies
Prostate Cancer and Prostatic Diseases (2019)
-
Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials
European Journal of Clinical Pharmacology (2017)
-
The best of both worlds — managing the cancer, saving the bone
Nature Reviews Endocrinology (2016)